Can Smartphone CBT Prevent Major Depression? What the RESiLIENT Trial Adds by Sarah Wilson Why Prevention Is The Right Frame Digital mental health tools are often judged as if they were trying to replace clinicians. That is the wrong starting point for the RESiLIENT trial. The more useful question is not whether a smartphone app…

What the EPISODE Trial Actually Changes in Treatment-Resistant Depression by PChina Jin LI (李锦) Psilocybin research in depression has become difficult to discuss without falling into one of two familiar narratives. In the first, psychedelics represent a long-awaited breakthrough: rapid, psychologically profound, and potentially transformative for patients who have not responded to conventional antidepressants. In…

How To Tell When a Psychiatric Study Is Truly Important, Not Just "Interesting" Introduction Psychiatric research produces no shortage of papers that sound intriguing on first reading. A new biomarker. A promising intervention. A surprising association. But scientific importance is not the same thing as novelty, and it is certainly not the same thing as…

The 5 Most Important Psychiatric Studies of April 2026: A Short Editorial Review Introduction Not every important psychiatric paper is dramatic on first reading. Some matter because they introduce a new treatment signal. Others matter because they make an old question more precise. The five studies below stood out in April 2026 not because they…

The Future of Erectile Dysfunction Treatment: What Will Replace Viagra and Cialis? Introduction Since their introduction in the late 1990s, phosphodiesterase type 5 (PDE5) inhibitors, most notably Viagra (sildenafil) and Cialis (tadalafil), have fundamentally reshaped the treatment of erectile dysfunction. For many men, these drugs remain effective, well tolerated, and convenient. Yet their limitations are…

Abuse, Diversion, and Mortality: How Gabapentinoids Entered the Illicit Drug Market Introduction Gabapentin was never expected to end up here, in toxicology reports, overdose surveillance dashboards, and European drug mortality registries. When it was introduced in the 1990s as an anticonvulsant, and later repurposed for neuropathic pain, gabapentin carried the comforting aura of a medication…

Sildenafil in 2025: A Fully Standardized Global Manufacturing Commodity Sildenafil Manufacturing in 2025: A Fully Standardized Generic Project In 2025, sildenafil has reached a stage that few once imagined for a drug that began its life as one of the most profitable pharmaceuticals in history: it is now a standardized industrial product, produced in high…

Counterfeit, “Natural,” and Gray-Market Sildenafil in 2025: A Major Challenge for the Legitimate Generic Industry France’s “Viagra honey” crisis and the rise of adulterated natural aphrodisiacs One of the most striking developments of 2025 in the European ED-drug landscape is the explosion of “Viagra honey”, also known as “love honey,” “miel aphrodisiaque,” or “miel bleu.”…

Global Prescription Status of Sildenafil in 2025: Over-the-Counter Is Rare Exception, Prescription the Rule Most of the world still requires a prescription for sildenafil Most of the world still requires a prescription for sildenafil As of 2025, in nearly all major markets, including the European Union, the United States, Canada, and many others, Sildenafil (generic…

A New "Super-Viagra" (Simenafil) and Its Consequences for the Generic Sildenafil Market Simenafil as a New PDE5 Inhibitor: What the Phase III Data Show Simenafil's arrival in 2025 marks the first genuinely new PDE5 inhibitor to reach late-stage clinical development in over a decade, and its emergence is being watched closely by both clinicians and…